News & Events » Press Releases

VIRxSYS Issued U.S. Patents for its Lentiviral Vector and SMaRT RNA Platforms

HIV Vaccine Achieves Functional Cure in Non-Human Primates

VIRxSYS to present data on two studies at IAS 2011

VIRxSYS Issued Two U.S. Patents for SMaRT™ RNA Platform for Gene

VIRxSYS Presents New Therapeutic Vaccine Data at HIV DART 2010

The VIRxSYS Corporation Joins Public Health Leaders to Discuss HIV Epidemic

VIRxSYS Corporation Demonstrates “Functional Cure” and Survival Benefit for the simian model of HIV in Preclinical Vaccine Study

VIRxSYS Presents HIV Vaccine Data at 2010 International AIDS Conference

VIRxSYS Presents Results from Multiple Studies at the 13th ASGCT Annual Meeting

Penn Researchers Present Phase II HIV Gene Therapy Trial Data at CROI 2010

VIRxSYS Announces at CROI Promising Results from Its HIV Vaccine Study

VIRxSYS Awarded Maryland Stem Cell Grant

VIRxSYS Publishes New Study on RNA Therapy

Penn Medicine presents HIV gene therapy trial data at CROI 2009

Shuyuan Zhang Joins VIRxSYS as Senior Director of Production

VIRxSYS to Host a Web Conference to Announce Clinical Trial Update

VIRxSYS To Present New VRX496™ Phase II HIV Gene Therapy Trial Data

VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia

VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial

VIRxSYS Corporation announced today, that it has acquired all the core technology and preclinical programs of Intronn Inc.

VIRxSYS Corporation announced today the presentation of a new analysis of safety data from Phase I and Phase II studies of VRX496™, their proprietary HIV-based lentiviral vector gene delivery system, at the American Society for Microbiology's 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago.

Gerard McGarrity Joins VIRxSYS as Executive Vice President of Scientific and Clinical Affairs

VIRxSYS and National Heart, Lung, and Blood Institute Sign Agreement

VIRxSYS Raises $20 Million in Financing

VIRxSYS Corporation Announces Publication of Phase I Study of Novel Gene Therapy for HIV

VIRxSYS Acquires Rights in Patents from Oxford Biomedica PLC which will Enhance Production of Lentiviral Vector Technology

First Patients Have Completed Infusions in Multiple-Dose Phase II Clinical Trial for HIV/AIDS Gene-Based Immunotherapy

First Patient Dosed In Phase II Clinical Trial For HIV/AIDS Gene Based Immunotherapy

VIRxSYS Announces Completion of Phase I Study Of VRX496™, Novel HIV Gene Therapy, And Plans To Initiate Phase II Study

VIRxSYS Completes $30 Million Financing, Funds Will Support Phase II Trial For HIV/AIDS

Novel HIV Gene Therapy Yields Exciting Results In Phase I Clinical Trial

Data Safety Monitoring Board Recommends Dosing of Final Two Patients

Third Patient To Be Treated with VRX496

Patent Granted: Methods for Stable Transduction of Cells with Viral Vectors

Data Safety Monitoring Board Unanimously Recommends Continuation of Phase 1 Clinical Trial

First Patient Dosing

Phase I Clinical Trial Initiated for Innovative Treatment of HIV/AIDS